Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDFAST study of eTRE Mediterranean diet versus Mysimba for liver fibrosis in adults with obesity-related cardiometabolic risk and MASLD-associated fibrosis
NL-OMON59564Phase 4Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of naltrexone + bupropion, bupropion and naltrexone in metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, obesity and 1 more (2 arms), sponsored by Franciscus Gasthuis & Vlietland. Started Apr 2025; status: recruiting.
02
Drugs
naltrexone + bupropionbupropionnaltrexone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosisobesityOverweight
Beyond the preview
Go deeper on NL-OMON59564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59564.